Immunovaccine Elects Marc Mansour, Ph.D. to Board of Directors

Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX
VENTURE:IMV), a clinical stage vaccine and immunotherapy company, today
announced the election of Marc Mansour, Ph.D., the Company's Chief Operating
Officer (COO), to its board of directors. Since joining Immunovaccine in 2001,
Dr. Mansour has led the development of Immunovaccine's DepoVax(TM) platform and
the Company's lead therapeutic cancer vaccine DPX-Survivac, which is poised for
randomized Phase 2 trials in ovarian cancer and glioblastoma. Previously serving
as Chief Science Officer, he was appointed the Company's COO in September 2013.


Albert Scardino, Executive Chairman of Immunovaccine, commented,

"Marc is the architect of our cancer immunotherapy program. This year he has
increasingly become the face of Immunovaccine to the investment community as he
has long been to the scientific community. His interaction with analysts,
bankers and investors in North America and Europe has raised the profile of the
company in this rapidly developing field of cancer treatment. We're pleased to
welcome him to the board."


Immunovaccine expects three trials to be initiated in 2014 with its cancer
immunotherapies that use a patented oil-based delivery system. The largest
study, a randomized Phase II trial of DPX-Survivac in ovarian cancer, will be
sponsored and conducted by Canada's NCIC Clinical Trials Group (NCIC CTG). The
trial is expected to begin enrolling the first of its 250 patients in 2014.


Additionally, researchers at the University of Rome have announced plans to
initiate a Phase II trial of DPX-Survivac in glioblastoma (brain cancer)
patients in the first half of 2014. A third trial, using DPX-0907 to treat
breast and ovarian cancer, is planned for initiation at Busto Arsizio Hospital
in Milan.


About Ovarian Cancer

Ovarian cancer accounts for more deaths than any other gynecologic cancer.
Symptoms do not occur until it is in the later stages of the disease, reducing
the chance for successful treatment and remission. It kills more than 100,000
women annually around the world. Improved surgical techniques have helped to
reduce the rate of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than four years. 


About Glioblastoma 

Glioblastoma, the most common form of brain cancer, is a fast-growing tumor type
that develops from astrocytes, a type of glial cell present in the brain. The
National Cancer Institute estimates that more than 23,000 Americans will be
diagnosed with brain and other nervous system tumors in 2013. Glioblastoma
accounts for approximately 15 percent of all brain tumors. The current standard
of care for glioblastoma patients calls for patients to receive maximum surgical
resection combined with radiation and concomitant and adjuvant temozolomide
therapy. Newly diagnosed glioblastoma patients have a median overall survival of
less than 24 months.


About Immunovaccine 

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvant to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. Connect at www.imvaccine.com


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the use of
proceeds of the financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Dr. Marc Mansour
Chief Operating Officer
Immunovaccine, Inc.
T: [phone]
E: [e-mail]


Tim Brons
Vida Strategic Partners (media)
T: [phone]
E: [e-mail]